Smith+Nephew confirmed failed merger talks with Johnson & Johnson's orthopaedics unit due to leadership disagreements. Consequently, the company cut its full-year revenue and profit forecasts citing p
reuters · 2026-11-03 23:34
Smith+Nephew reduced its full-year revenue growth forecast to approximately 4% due to persistent weakness in US knee and hip implant demand. The company expects new product launches to cushion the imp
reuters · 2026-08-03 23:13
Smith+Nephew reported a 3.1% rise in underlying Q1 revenue to $1.5 billion, maintaining its annual outlook while announcing a $500 million share buyback amidst supply chain challenges.
reuters · 2026-05-05 23:21
ChemBrief